A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, without Inhibitory Antibodies to Factor VIII or IX (ATLAS-A/B)

August 09, 2018
https://clinicaltrials.gov/ct2/show/NCT03417245
Hematology Non Malignant
Principal Investigator: Philip Kuriakose, MD

 Fitusiran, Hemophilia A or B, Inhibitory Antibodies, Factor VIII or IX 

Accepting Participants